Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Leukemia, Myeloid, Acute 15Leukemia, Lymphocytic, Chronic, B-Cell 11Burkitt Lymphoma 10Lymphoma 9Leukemia 9Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Lymphoma, Follicular 8Lymphoma, Non-Hodgkin 7Lymphoma, Mantle-Cell 7Lymphoma, B-Cell, Marginal Zone 7Myelodysplastic Syndromes 6Multiple Myeloma 6Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 5Myeloproliferative Disorders 5Lymphoma, Large B-Cell, Diffuse 5Hodgkin Disease 5Lymphoma, Large-Cell, Immunoblastic 4Leukemia, Myelomonocytic, Chronic 4Leukemia, Myeloid, Chronic-Phase 4Leukemia, Myeloid, Accelerated Phase 4Hematologic Neoplasms 4Congenital Abnormalities 4Sezary Syndrome 3Mycosis Fungoides 3Lymphoma, T-Cell, Cutaneous 3Leukemia, Biphenotypic, Acute 3Waldenstrom Macroglobulinemia 2Recurrence 2Primary Myelofibrosis 2Neoplasms, Plasma Cell 2

Interventions

fludarabine phosphate 1fludarabine 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Mesothelin-positive Advanced Refractory Solid Tumors × fludarabine phosphate × Clear all
NCT05531708 2023-03-01

Exploratory Study of Novel MSLN CAR-T Cell Therapy in Patients With MSLN-positive Advanced Refractory Solid Tumors

Shanghai Pudong Hospital

Phase 1 Withdrawn
Other solid neoplasm

Mesothelin-positive Advanced Refractory Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡